Flonoltinib not checked
Chengdu Zenitar Biomedical Technology Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Flonoltinib Maleate Tablet 100mg, oral administration, once daily, given on an empty stomach for 8 consecutive weeks of treatment.”In the company’s words, NCT07232290 on ClinicalTrials.gov
- Tested for
- MF (2 trials), MF,PMF,PPV-MF,PET-MF, Polycythemia Vera (PV), Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, Myelofibrosis With Myeloid Metaplasia and 8 more
- Main trialPhase 3
- “This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.”In the company’s words, NCT07317700 on ClinicalTrials.gov
Other drugs for MF
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up5
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2027 | A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis | |
| Phase 2Active, not recruiting | 26 Nov 2025 | A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis | |
| Phase 2Recruiting | 30 Jul 2027 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | |
| Phase 2Recruiting | 30 Dec 2027 | A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis | |
| Phase 2Not yet recruiting | Nov 2028 | Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis | |
| Phase 1Not yet recruiting | 30 Dec 2026 | Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets | |
| Phase 1/2Completed | 29 Nov 2023 | Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | |
| Phase 1Completed | 15 Aug 2024 | A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects | |
| Phase 1Completed | 25 Jul 2026 | Mass Balance Study of [14C] Flonoltinib Maleate |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026